1. Home
  2. POLE vs AQST Comparison

POLE vs AQST Comparison

Compare POLE & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • POLE
  • AQST
  • Stock Information
  • Founded
  • POLE 2024
  • AQST 2004
  • Country
  • POLE United States
  • AQST United States
  • Employees
  • POLE N/A
  • AQST N/A
  • Industry
  • POLE
  • AQST Biotechnology: Pharmaceutical Preparations
  • Sector
  • POLE
  • AQST Health Care
  • Exchange
  • POLE NYSE
  • AQST Nasdaq
  • Market Cap
  • POLE 299.8M
  • AQST 272.9M
  • IPO Year
  • POLE 2024
  • AQST 2018
  • Fundamental
  • Price
  • POLE N/A
  • AQST $3.74
  • Analyst Decision
  • POLE
  • AQST Strong Buy
  • Analyst Count
  • POLE 0
  • AQST 6
  • Target Price
  • POLE N/A
  • AQST $10.67
  • AVG Volume (30 Days)
  • POLE 14.3K
  • AQST 1.5M
  • Earning Date
  • POLE 01-01-0001
  • AQST 08-05-2025
  • Dividend Yield
  • POLE N/A
  • AQST N/A
  • EPS Growth
  • POLE N/A
  • AQST N/A
  • EPS
  • POLE N/A
  • AQST N/A
  • Revenue
  • POLE N/A
  • AQST $54,228,000.00
  • Revenue This Year
  • POLE N/A
  • AQST N/A
  • Revenue Next Year
  • POLE N/A
  • AQST $45.71
  • P/E Ratio
  • POLE $58.59
  • AQST N/A
  • Revenue Growth
  • POLE N/A
  • AQST 5.29
  • 52 Week Low
  • POLE $9.94
  • AQST $2.12
  • 52 Week High
  • POLE $11.16
  • AQST $5.80
  • Technical
  • Relative Strength Index (RSI)
  • POLE N/A
  • AQST 68.54
  • Support Level
  • POLE N/A
  • AQST $3.13
  • Resistance Level
  • POLE N/A
  • AQST $3.33
  • Average True Range (ATR)
  • POLE 0.00
  • AQST 0.22
  • MACD
  • POLE 0.00
  • AQST 0.01
  • Stochastic Oscillator
  • POLE 0.00
  • AQST 94.10

About POLE ANDRETTI ACQUISITION CORP. II

Andretti Acquisition Corp II is a blank check company.

About AQST Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Share on Social Networks: